Enveric Biosciences, Inc. announced Frank Pasqualone was appointed to the board of directors, to serve as a director of the Board, to fill a vacancy as a result of the increase in the size of the Board from eight to nine persons, effective as of the same date, for a term expiring at the 2022 annual meeting of the Company's stockholders, or until Mr. Pasqualone's successor is duly elected and qualified, or his earlier death, resignation or removal. There are no arrangements or understandings between Mr. Pasqualone and any other persons pursuant to which Mr. Pasqualone was selected to serve as a director the Company. In addition, there are no transactions between the Company and Mr. Pasqualone or his immediate family members requiring disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended.